Although CCR5 ligand levels were not measured in this study, the effect of CCR5 antagonist in different subgroups (mild, moderate, versus severe cognitive impairment) in the overall cohort could depend on the levels of CCR5 endogenous ligands in the CSF. The gene discussed is CCR5; the disease is Cognitive impairment.